#mannkindcorporation — Public Fediverse posts

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

MannKind If approved, ReadyFlow Autoinjector …
#NewsBeep #News #Medication #AU #Australia #Autoinjector #chronicheartfailure #ChronicKidneyDisease #foodanddrugadministration #FUROSCIX #Furosemide #Health #MannKindCorporation #patients #treatment
https://www.newsbeep.com/au/322892/

https://www.europesays.com/ie/210649/ MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease #Autoinjector #ChronicHeartFailure #ChronicKidneyDisease #Éire #FoodAndDrugAdministration #FUROSCIX #Furosemide #Health #IE #Ireland #MannKindCorporation #Medication #patients #treatment

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

MannKind If approved, ReadyFlow Autoinjec…
#NewsBeep #News #Medication #Autoinjector #chronicheartfailure #chronickidneydisease #foodanddrugadministration #FUROSCIX #Furosemide #Health #MannKindCorporation #Patients #treatment #UK #UnitedKingdom
https://www.newsbeep.com/uk/294068/

https://www.europesays.com/uk/606295/ MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease #Autoinjector #ChronicHeartFailure #ChronicKidneyDisease #FoodAndDrugAdministration #FUROSCIX #Furosemide #Health #MannKindCorporation #Medication #patients #treatment #UK #UnitedKingdom

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation…
#NewsBeep #News #Medication #CA #Canada #DataSafetyMonitoringBoard #Health #lungdisease #Lungfunction #MannKindCorporation #NTM #primaryendpoint #sputumculture
https://www.newsbeep.com/ca/274862/

https://www.europesays.com/ie/173617/ MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease #DataSafetyMonitoringBoard #Éire #Health #IE #Ireland #LungDisease #LungFunction #MannKindCorporation #Medication #NTM #PrimaryEndpoint #SputumCulture

https://www.europesays.com/uk/561703/ MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease #DataSafetyMonitoringBoard #Health #LungDisease #LungFunction #MannKindCorporation #Medication #NTM #PrimaryEndpoint #SputumCulture #UK #UnitedKingdom